News | PET Imaging | August 02, 2016

PET Imaging Could Provide Helpful Information for Genetically Linked Lung Cancer

Big data may help determine best treatment, suggests large study

PET, positron emission tomography, genetically linked lung cancer, AAPM, big data

August 2, 2016 — A cutting-edge method of extracting big data from positron emission tomography (PET) images can provide additional information to quantify lung tumors caused by a genetic mutation. This information could help guide the most effective treatment, suggest findings of a study of nearly 350 patients being presented at the 58th Annual Meeting of the American Association of Physicists in Medicine (AAPM), July 31-Aug. 4 in Washington, D.C.

Advances in genomics – the analysis of an organism’s genetic information – have shown that non-small cell lung cancer (NSCLC), the most common type of lung cancer, often is caused by mutations in specific genes. These mutations include epidermal growth factor receptor (EGFR) and Kristen rat sarcoma viral (KRAS). For example, 15 percent of patients have EGFR mutations and often benefit from tyrosine kinase inhibitor (TKI) therapies. Therefore, identification of these mutations is crucial for selecting the most effective treatment for these patients. 

PET imaging often is used to assess tumor glucose metabolism and an essential tool for lung cancer management. Studies have shown that some of the biological and genetic variations within tumors potentially can be captured in PET images.

Using big data radiomics — extracting comprehensive information from PET images — researchers evaluated the associations between radiomic features of tumors and EGFR and KRAS mutations in about 350 NSCLC lung cancer patients. The mutations were confirmed by molecular testing based on biopsies of tumor tissues, the standard of care for mutation identification. Researchers found that radiomic features describing different aspects of the tumor, such as its shape and textures, appear to be associated with EGFR mutations. Their results suggest that different metabolic imaging patterns (or imaging phenotypes) that are quantified by radiomic features may be caused by EGFR mutations.

“Our long-term goal would be to use PET or another imaging technique to develop non-invasive imaging biomarkers that complement molecular tests,” said Hugo Aerts, Ph.D., director of the Computational Imaging and Bioinformatics Laboratory at Dana Farber Cancer Institute, Brigham and Women’s Hospital and Harvard Medical School in Boston.

“Medical images are regularly acquired for every cancer patient that comes into our clinic for treatment, which is the case at many other cancer centers as well,” said Stephen Yip, Ph.D., an instructor at Harvard Medical School, Dana Farber Cancer Institute and Brigham and Women’s Hospital. “This early research suggests that standard-of-care PET imaging may help guide doctors in identifying patients with EGFR mutations, potentially providing valuable information for personalized lung cancer therapy.”

“More research needs to be done to further understand the complementary role of PET imaging to molecular testing,” Aerts said.

The researchers are now assessing combining PET-based radiomic features with features derived from other imaging tests, such as computed tomography (CT) or magnetic resonance imaging (MRI), to improve the accuracy of genetic mutation identification in lung and brain cancers.

For more information: www.aapm.org

Related Content

IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology, and SCK CEN (Belgian Nuclear Research Center) announced a strategic R&D partnership to enable the production of Actinimum-225 (225Ac), a novel radioisotope which has significant potential in the treatment of cancer.
News | Radiation Oncology | September 17, 2021
September 17, 2021 — IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology, a
Strategies to help guide nuclear radiology teams at various healthcare systems in 2021 and beyond
Feature | Nuclear Imaging | September 16, 2021 | By Staff of the American Society of Nuclear Cardiology (ASNC)
A year after COVID-19 turned the world upside do
Revised guidelines for lung cancer screening eligibility are perpetuating disparities for racial/ethnic minorities, according to a new study in Radiology.

Getty Images

News | Lung Imaging | September 15, 2021
September 15, 2021 — Revised guidelines for...
Evaluation of therapeutic efficacy of drug candidates in preclinical oncology with positron emission tomography (PET)

Getty Images

Feature | PET Imaging | September 14, 2021 | By Todd Sasser, Ph.D.
Plan to attend RSNA21 at McCormick Place Chicago, Nov. 28 – Dec. 2, 2021

Getty Images

News | RSNA | September 13, 2021
September 13, 2021 — The Radiological Society of North America (RSNA) today announced highlights of the Technical Exh
Laws designed to help women with increased risk for missed breast cancer diagnoses may help catch the disease earlier, according to Penn State College of Medicine researchers.

Getty Images | AleksandarNakic

News | Breast Imaging | September 09, 2021
September 9, 2021 — Laws designed to help women with increased risk for...

Image of a STING protein, courtesy of UCLA Jonsson Comprehensive Cancer Center

News | PET Imaging | September 08, 2021
September 8, 2021 — A new study from scientists at the UCLA Jonsso...